Ph.D., and Boris Sepesi, M.D. Tina...Bruton, Jr. Chair Boris Sepesi, M.D. Associate...V. Heymach, and Boris Sepesi Natasha M. Flores
Lung cancer is the deadliest cancer in the US. But it’s also highly preventable.
Promising clinical results with combination treatments for patients with melanoma and lung cancer highlight immunotherapy advances being presented by researchers from The University of Texas MD Anderson Cancer Center at The Society for Immunotherapy of Cancer (SITC) 35th Anniversary Annual Meeting & Pre-Conference Programs (SITC 2020).
The Thoracic Surgery Fellowship provides a balanced education in the treatment of cardiovascular, esophageal, pulmonary and other thoracic diseases. Lean more about this opportunity.
By the time Sam Markota’s rectal cancer was diagnosed, it had already spread to his liver and lung. After one first oncologist gave him only a few years to live, he came to MD Anderson in Katy for a second opinion.
Anne S. Tsao, MD, Department of Thoracic-Head & Neck Med Onc, Division of Cancer Medicine
The Linghua Wang Lab at MD Anderson uses genomics to understand how tumors react to cancer treatments. See publications from the Wang Lab here.
MD Anderson researchers have identified a tenacious subset of immune macrophages that thwart treatment of glioblastoma with immunotherapy by expressing CD73, providing a new potential drug target against the tumor.
The first randomized Phase II clinical trial to report on single and combined neoadjuvant immune checkpoint inhibitor therapy in stage I-III non-small cell lung cancer (NSCLC) found combination therapy produced a significant clinical benefit, researchers from The University of Texas MD Anderson Cancer Center reported in Nature Medicine.
Radiation or surgical removal of metastatic tumors provides a major survival advantage for lung cancer patients with minimal stage 4 disease who have not progressed after frontline chemotherapy, a study led by researchers from The University of Texas MD Anderson Cancer Center shows.|Radiation or surgical removal of metastatic tumors provides a major survival advantage for lung cancer patients with minimal stage 4 disease who have not progressed after frontline chemotherapy, a study led by researchers from The University of Texas MD Anderson Cancer Center shows.